Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors

Background: Targeted therapy has been established as the standard-of-care for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Among patients with advanced lung cancer, 30–40% have bone metastases (BoM) at first diagnosis. However, lit...

Full description

Bibliographic Details
Main Authors: Yue-Yun Chen, Pei-Pei Wang, Yang- Fu, Qing- Li, Jiang-Fang Tian, Ting- Liu, Zhen Lin, Zhen-Yu Ding
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Journal of Bone Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137421000233